tiprankstipranks
Trending News
More News >
Eurofins Scientific (FR:ERF)
:ERF

Eurofins Scientific (ERF) AI Stock Analysis

Compare
34 Followers

Top Page

FR

Eurofins Scientific

(LSE:ERF)

Rating:74Outperform
Price Target:
€64.00
▲(4.88%Upside)
Eurofins Scientific's strong financial performance and positive technical indicators are balanced by a relatively high valuation. The stock benefits from robust cash flow and positive market momentum, making it an attractive option despite valuation concerns.

Eurofins Scientific (ERF) vs. iShares MSCI France ETF (EWQ)

Eurofins Scientific Business Overview & Revenue Model

Company DescriptionEurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. The company offers a portfolio of approximately 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability, and purity of various products. It provides services such as agro-science, including biological assessment, consumer and human, and environmental safety, product chemistry, regulatory consultancy, and seed services; agro testing; assurance, such as product inspection, auditing, certification, training and consultation of food, consumer products, and healthcare and cosmetics; biopharma, and clinical diagnostics. In addition, the company offers consumer product testing, which include product compliance and audit, testing, certifications and approvals, inspections, training courses, and digital media and cyber security for various industries; cosmetics and personal care; environment testing, including water, air, soil, waste, and other products testing; and food and feed testing that include allergen, GMO, grain, meat, nano material, pesticides, and residual DNA testing. Further, it offers audit and certification, authenticity, carbohydrates, consulting, dioxins and POPs, food irradiation, labelling, law, heavy metals, identity preservation, mealtime, molecular and microbiology, mycotoxins, nutritional analyses, organic containments, packaging/migration, radioactivity, rapidest, sensorsy and consumer research, trainings, veterinary drug residues, and vitamins services. Additionally, the company provides forensic, genomic, maritime, materials and engineering, REACH, and technologies services. It operates approximately 900 laboratories in 54 countries. The company was founded in 1987 and is headquartered in Luxembourg City, Luxembourg.
How the Company Makes MoneyEurofins Scientific generates revenue primarily through the provision of testing and laboratory services. Its key revenue streams include analytical testing services for food and feed, environmental testing, pharmaceutical testing, and clinical diagnostics. The company serves a broad range of industries, including agriculture, food and beverage, pharmaceuticals, biotechnology, and healthcare, which require regular testing to comply with regulatory standards and ensure product safety and quality. Eurofins' extensive network of laboratories and its investment in cutting-edge technology enable it to deliver high-quality services efficiently, which drives client retention and attracts new business. Strategic acquisitions and partnerships also play a significant role in expanding its service capabilities and geographical reach, further contributing to its revenue growth.

Eurofins Scientific Financial Statement Overview

Summary
Income Statement
Balance Sheet
Cash Flow
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue8.38B6.95B6.51B6.71B6.72B5.44B
Gross Profit1.02B4.71B620.40M4.49B4.57B3.69B
EBITDA1.60B1.40B1.22B1.36B1.71B1.28B
Net Income321.75M406.40M310.30M610.20M782.60M539.40M
Balance Sheet
Total Assets10.89B10.89B10.89B10.08B9.33B8.58B
Cash, Cash Equivalents and Short-Term Investments1.22B613.90M1.22B486.60M515.30M912.40M
Total Debt4.93B3.61B3.93B3.33B2.75B3.15B
Total Liabilities6.75B5.50B5.75B5.23B4.66B4.86B
Stockholders Equity4.08B5.34B5.08B4.78B4.65B3.69B
Cash Flow
Free Cash Flow870.15M790.50M467.80M476.10M990.30M868.00M
Operating Cash Flow1.50B1.32B1.02B1.14B1.51B1.22B
Investing Cash Flow-1.02B-846.50M-681.10M-855.90M-1.03B-525.00M
Financing Cash Flow-211.55M-1.09B495.80M-311.30M-910.30M-48.60M

Eurofins Scientific Technical Analysis

Technical Analysis Sentiment
Positive
Last Price61.02
Price Trends
50DMA
57.64
Positive
100DMA
53.32
Positive
200DMA
51.13
Positive
Market Momentum
MACD
1.00
Positive
RSI
62.06
Neutral
STOCH
76.11
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ERF, the sentiment is Positive. The current price of 61.02 is above the 20-day moving average (MA) of 59.89, above the 50-day MA of 57.64, and above the 200-day MA of 51.13, indicating a bullish trend. The MACD of 1.00 indicates Positive momentum. The RSI at 62.06 is Neutral, neither overbought nor oversold. The STOCH value of 76.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:ERF.

Eurofins Scientific Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
FRERF
74
Outperform
€11.05B28.459.66%0.86%6.70%32.29%
51
Neutral
$7.50B0.32-61.87%2.27%17.10%1.59%
€14.00B32.2210.86%0.76%
€8.60B24.988.89%1.35%
€19.96B97.695.24%0.34%
€252.14M62.802.27%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
FR:ERF
Eurofins Scientific
61.02
13.62
28.75%
GB:0RUG
bioMerieux
118.49
25.36
27.23%
GB:0MH6
Ipsen
102.70
-7.60
-6.89%
GB:0RG8
Sartorius Stedim Biotech
204.00
45.26
28.51%
DE:E8TN
Eurobio-Scientific SA
25.05
11.35
82.85%
DE:ZEP2
Eurofins-Cerep SA
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 05, 2025